– Yunding Xinyao (云顶新耀) experiences a stock price decline exceeding 20% following the approval of a generic version of its blockbuster kidney drug Nefecon (耐赋康).
– The generic drug by Hainan Herui Pharmaceutical Co., Ltd. (海南合瑞制药股份有限公司) tests China’s patent linkage system, with declarations that could allow early market entry.
– Major pharmaceutical firms Shijiazhuang Pharmaceutical Group Zhongnuo Pharmaceutical (石药集团中诺药业（石家庄）有限公司) and Qilu Pharmaceutical Co., Ltd. (齐鲁制药有限公司) are also advancing generic versions, posing further competitive threats.
– Legal experts outline potential pathways for Yunding Xinyao to challenge generic approvals under China’s Early Resolution Mechanism for Drug Patent Disputes.
– The Nefecon generic competition signals broader implications for innovation, patent protection, and investment strategies in China’s biopharma sector.
A seismic shockwave hit the Chinese biopharmaceutical market in late December 2025, as Yunding Xiyao (云顶新耀), a Hong Kong-listed innovator, saw its share price tumble more than 20% over a single week. The catalyst was the regulatory approval of a generic copycat for its crown jewel, the IgA nephropathy drug Nefecon (布地奈德肠溶胶囊)—a therapy that had achieved annualized sales surpassing RMB 10 billion within its first full year on the market. This Nefecon generic competition not only threatens a significant revenue stream for Yunding Xinyao but also serves as a high-stakes test case for China’s evolving pharmaceutical patent landscape. For global investors and industry watchers, the episode underscores the delicate balance between fostering innovation and encouraging affordable access in the world’s second-largest drug market. The immediate financial fallout is clear, but the long-term ramifications for patent strategy, regulatory enforcement, and sector valuation are now under intense scrutiny.
The Nefecon Blockbuster: A Clinical and Commercial Success Story
Nefecon, known generically as budesonide enteric-coated capsules, is not just another drug; it represents a paradigm shift in treating primary IgA nephropathy, a kidney disease that often leads to end-stage renal failure. Originally licensed from Swedish biopharma Calliditas Therapeutics, Nefecon was introduced to China by Yunding Xinyao in 2019 and received marketing authorization from the National Medical Products Administration (NMPA, 国家药品监督管理局) in November 2023.
Innovative Mechanism and Market Adoption
The drug’s innovation lies in its targeted delivery system. As a gut-selective immunomodulator, Nefecon employs a unique delayed and sustained-release formulation to precisely deliver budesonide to the ileum—the site of pathogenic galactose-deficient IgA1 production. This approach intervenes at the disease source, significantly slowing kidney function decline. Clinically, it filled a critical unmet need in China, where an estimated millions suffer from IgA nephropathy. Following its commercial launch in May 2024, Nefecon was swiftly included in China’s National Reimbursement Drug List (NRDL, 国家医保药品目录), ensuring broad patient access and fueling rapid sales growth. Yunding Xinyao disclosed that Nefecon sales exceeded RMB 10 billion in the first three quarters of 2025 alone, cementing its status as a blockbuster therapy.
The Generic Onslaught: First Copycat and Looming Threats
The tranquility of this commercial success was shattered on December 22, 2025, when the NMPA website published drug approval documents revealing that Hainan Herui Pharmaceutical Co., Ltd. (海南合瑞制药股份有限公司) had received approval for its generic version of budesonide enteric-coated capsules on December 16. This marked the first successful generic challenge to Nefecon, directly triggering the Nefecon generic competition that rattled investors.
Patent Declarations and the Race to Market
Under China’s Early Resolution Mechanism for Drug Patent Disputes, chemical generic applicants must declare their stance on relevant patents listed in the China Marketed Drug Patent Information Registration Platform. Hainan Herui filed a “Category 3” declaration, promising not to market its generic until Yunding Xinyao’s core patent expires on May 7, 2029. However, the approval itself suggests regulatory acceptance, raising immediate questions about patent enforcement. Yunding Xinyao issued a statement asserting that its patents remain valid and that it reserves the right to take all subsequent legal actions. More concerning for the company is the advanced progress of two other pharmaceutical giants: Shijiazhuang Pharmaceutical Group Zhongnuo Pharmaceutical (石药集团中诺药业（石家庄）有限公司) and Qilu Pharmaceutical Co., Ltd. (齐鲁制药有限公司). Both have generic applications in the上市申请阶段 (application for marketing stage) with “Category 4.2” declarations, claiming their products do not fall within the protection scope of Yunding Xinyao’s patents. This Nefecon generic competition could intensify if these firms successfully argue they have designed around the patents, potentially launching years ahead of the 2029 expiry.
Legal Battleground: China’s Patent Linkage System Under Scrutiny
This unfolding drama places China’s pharmaceutical patent linkage system squarely in the spotlight. Established by the NMPA and the China National Intellectual Property Administration (CNIPA, 国家知识产权局) in July 2021, the “Measures for the Implementation of the Early Resolution Mechanism for Drug Patent Disputes (Trial)” (药品专利纠纷早期解决机制实施办法（试行）) aims to balance innovation protection with the development of high-quality generic drugs.
Mechanisms and Legal Recourse
The system links drug marketing approval procedures with patent dispute resolution. For a declared generic like those from Shijiazhuang and Qilu, Yunding Xiyao has a 45-day window from the public disclosure of the application to initiate litigation or request an administrative ruling on whether the generic infringes its patents. Legal expert Meng Fanchen (孟凡臣), senior partner at Beijing Weibo Law Firm, explains, “If Yunding Xinyao disputes the patent declarations, it can file a lawsuit with the People’s Court or seek an administrative ruling from CNIPA within 45 days. Any party dissatisfied with CNIPA’s ruling can appeal to the court.” Conversely, if the patent holder does not act within this period, the generic applicant can sue for a declaratory judgment of non-infringement, as noted by lawyer Yang Cheng (杨铖) of Beijing Longan (Shenzhen) Law Firm. This legal framework is now being stress-tested by the Nefecon generic competition, with outcomes that could set precedents for future disputes.
Strategic Responses: How Yunding Xinyao Can Defend Its Turf
Facing this multi-front generic assault, Yunding Xinyao must deploy a combination of scientific, regulatory, and legal strategies to protect its market position. The company’s initial public statements hint at its tactical approach.
Scientific and Regulatory Arguments
Yunding Xinyao has emphasized that for a complex drug like Nefecon, traditional bioequivalence (BE) trials based on systemic drug exposure may not adequately predict clinical efficacy and safety. The company argues that generics should require large-sample clinical studies to confirm therapeutic equivalence—a hurdle that could delay or deter copycat approvals. This stance leverages the drug’s innovative formulation to raise the bar for generic entrants, potentially buying time in regulatory reviews. Moreover, the company can pursue aggressive patent litigation to enforce its intellectual property rights. As Zhou Liyun (周立运), chairman of pharmaceutical data firm PharmCube (医药魔方), observes, “The patent system itself balances protecting innovation and encouraging patent challenges. From the originator’s perspective, they aim to enhance patent barriers and extend protection through layered strategies, which in turn stimulates more innovation.”
Market Implications: Investor Sentiment and Sector Outlook
The immediate market reaction—a over 20% plunge in Yunding Xinyao’s stock—reflects investor anxiety over eroded future earnings. However, the broader implications of this Nefecon generic competition extend far beyond a single company’s share price.
Valuation Pressures and Investment Considerations
For investors in Chinese biopharma, this event highlights the critical importance of robust patent portfolios and lifecycle management strategies. Companies relying on blockbuster drugs with imminent patent cliffs may face heightened scrutiny, potentially leading to valuation discounts. Conversely, firms with strong pipelines, diversified portfolios, or expertise in hard-to-copy biologics could be viewed more favorably. The situation also underscores the need for deep due diligence on China’s regulatory nuances. Investors must now factor in not just clinical and commercial risks, but also the evolving legal landscape surrounding patent linkages. As Meng Fanchen (孟凡臣) cautions, “This case will ultimately return to the determination of technical facts and application of law. Regardless of the outcome, there is no need for overinterpretation.” Yet, the market is clearly signaling that patent challenges can have swift and severe financial consequences.
Forward-Looking Guidance for Stakeholders
The Nefecon generic competition saga is more than a corporate setback; it is a defining moment for China’s pharmaceutical innovation ecosystem. For Yunding Xinyao, the path forward involves vigorous legal defense, potential appeals to regulatory bodies, and accelerated development of its broader pipeline to reduce dependence on a single asset. For generic players, the case demonstrates both opportunities and perils in navigating patent declarations and formulation innovations. For regulators, it presents an opportunity to refine the early resolution mechanism, ensuring it truly incentivizes original research while facilitating timely generic entry. And for investors, this episode serves as a stark reminder to assess patent durability and competitive landscapes meticulously. As China continues to integrate into global pharmaceutical markets, the outcomes of such disputes will shape investment theses and strategic decisions for years to come. Stakeholders should monitor court rulings, regulatory updates, and company announcements closely, as the final chapter in this Nefecon generic competition is yet to be written.